menu
    • menu
    [{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeoVax Labs \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"GeoVax Labs \/ Undisclosed"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COH04S1","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeoVax Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Labs \/ Undisclosed"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COH04S1","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeoVax Labs \/ City of Hope","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Labs \/ City of Hope"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"GEO-CM01","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeoVax Labs \/ GeoVax Labs","highestDevelopmentStatusID":"4","companyTruncated":"GeoVax Labs \/ GeoVax Labs"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GEO-CM02","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GeoVax Labs \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"GeoVax Labs \/ Undisclosed"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"BravoVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"2019-nCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeoVax Labs \/ GeoVax Labs","highestDevelopmentStatusID":"1","companyTruncated":"GeoVax Labs \/ GeoVax Labs"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Ad\/PNP","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeoVax Labs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GeoVax Labs \/ Undisclosed"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Stanford University | Gabrail Cancer Center Research | Thomas Jefferson University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"Adenovirus Loaded Purine Nucleoside Phosphorylase","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeoVax Labs \/ Stanford University | Gabrail Cancer Center Research | Thomas Jefferson University","highestDevelopmentStatusID":"7","companyTruncated":"GeoVax Labs \/ Stanford University | Gabrail Cancer Center Research | Thomas Jefferson University"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"EmVenio Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"GEO-CM04S1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeoVax Labs \/ EmVenio Research","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Labs \/ EmVenio Research"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"GEO-D03 DNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeoVax Labs \/ GeoVax Labs","highestDevelopmentStatusID":"6","companyTruncated":"GeoVax Labs \/ GeoVax Labs"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GOVX-B11","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeoVax Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Labs \/ Undisclosed"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"AIDS Research Consortium of Atlanta | University of Alabama at Birmingham | AIDS Research Alliance","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"JS7 plasmid DNA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeoVax Labs \/ AIDS Research Consortium of Atlanta | University of Alabama at Birmingham | AIDS Research Alliance","highestDevelopmentStatusID":"6","companyTruncated":"GeoVax Labs \/ AIDS Research Consortium of Atlanta | University of Alabama at Birmingham | AIDS Research Alliance"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Advanced Bioscience laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"MVA-Based SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeoVax Labs \/ Advanced Bioscience laboratories","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Labs \/ Advanced Bioscience laboratories"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MVA-MARV-VLP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeoVax Labs \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"GeoVax Labs \/ Undisclosed"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Synthetic MVA-based SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeoVax Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Labs \/ Undisclosed"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Sino Biological","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeoVax Labs \/ GeoVax Labs","highestDevelopmentStatusID":"1","companyTruncated":"GeoVax Labs \/ GeoVax Labs"}]

    Find Clinical Drug Pipeline Developments & Deals by GeoVax Labs

    Menu

    GeoVax Labs

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MVA-Based SARS-CoV-2 Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Advanced Bioscience laboratories

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates

                            Details : The partnership will support current Good Manufacturing Practices production of the company’s vaccine candidates, including GEO-MVA and GEO-CM04S1 (MVA-based SARS-CoV-2 vaccine), a next-generation COVID-19 vaccine based on GeoVax’s MVA viral vector p...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 31, 2023

                            Lead Product(s) : MVA-Based SARS-CoV-2 Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Advanced Bioscience laboratories

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GEO-CM04S1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : EmVenio Research

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial

                            Details : GEO-CM04S1 is a synthetic attenuated modified vaccinia Ankara (sMVA) vector vaccine that expresses spike and nucleocapsid antigens of the SARS-CoV-2 (COVID-19) virus.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 15, 2023

                            Lead Product(s) : GEO-CM04S1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : EmVenio Research

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ad/PNP,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

                            Details : Gedeptin (Ad/PNP) is a gene-directed enzyme prodrug therapy (GDEPT) that results in the formation of the oncolytic agent within the tumor itself, resulting in tumor cell death while significantly limiting systemic exposure.

                            Product Name : Gedeptin

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 07, 2023

                            Lead Product(s) : Ad/PNP,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COH04S1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : City of Hope

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows It Produced Ro...

                            Details : A COVID-19 investigational vaccine COH04S1, elicited neutralizing antibodies against the virus’ spike protein also, produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in Phase 1 clinical tria...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 10, 2022

                            Lead Product(s) : COH04S1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : City of Hope

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GEO-CM02

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress

                            Details : GeoVax’s vaccine design strategy for developing a universal SARS-CoV-2 vaccine and presented efficacy and immunogenicity data for the Company’s lead vaccine candidate, GEO-CM02, which encodes the Spike (S), Membrane (M) and Envelope (E) proteins.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 17, 2021

                            Lead Product(s) : GEO-CM02

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Synthetic MVA-based SARS-CoV-2 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

                            Details : Synthetic MVA-based SARS-CoV-2 Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 26, 2021

                            Lead Product(s) : Synthetic MVA-based SARS-CoV-2 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COH04S1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

                            Details : COH04S1 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 20, 2020

                            Lead Product(s) : COH04S1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GEO-CM01

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development

                            Details : The Patent License Agreement to GeoVax includes access to NIAID’s patent rights in the stabilized SPIKE protein, which is the protein that SARS-CoV-2 uses to gain entry into human tissue.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 26, 2020

                            Lead Product(s) : GEO-CM01

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MVA-MARV-VLP Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GeoVax Announces Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus S...

                            Details : The study demonstrated that guinea pigs vaccinated with GeoVax’s developmental MVA-MARV-VLP vaccine were 100% protected against death and disease caused by the Angola strain of Marburg virus.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 03, 2020

                            Lead Product(s) : MVA-MARV-VLP Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            GeoVax Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : Sino Biological

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            GeoVax and Sino Biological Establish Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (CO...

                            Details : Sino Biological will provide key bioreagents such as recombinant proteins, antibodies and detection kits for use in COVID-19 vaccine development underway at GeoVax.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 30, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Sino Biological

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth